论文部分内容阅读
目的 :分析人非小细胞肺癌(non-small cell carcinoma,NSCLC)组织中c-Myc基因的表达,探讨沉默c-Myc基因在非小细胞肺癌基因治疗中的前景。方法:应用实时荧光定量PCR法检测84例非小细胞肺癌组织及其相应癌旁组织中c-Myc基因mRNA的表达情况。通过脂质体Lipofact AMINE2000将c-Myc基因siRNA瞬时转染至非小细胞肺癌H1299癌株细胞中,顺铂(Cisplatin,cis)药物毒性实验验证c-Myc基因沉默对肿瘤细胞的抑制效果。应用RT-PCR检测H1299细胞中c-Myc基因RNA的表达,CCK-8法检测抑制细胞的效果。结果 :非小细胞肺癌组织中c-Myc基因m RNA的表达水平高于相应的癌旁组织,差异有统计学意义(P<0.05)。c-Myc si RNA瞬时转染后的H1299细胞中,c-Myc基因m RNA的表达水平显著下降(P<0.05)。将c-Myc基因沉默和顺铂联合使用,还可以显著提高顺铂对H1299细胞增殖的抑制效果(P<0.05)。结论 :c-Myc基因在非小细胞肺癌组织中的表达水平明显高于相应癌旁组织,沉默c-Myc基因能显著提高顺铂抑制非小细胞肺癌H1299细胞增殖的作用,c-Myc基因有可能成为NSCLC基因治疗的新靶点。
Objective: To analyze the expression of c-Myc gene in human non-small cell carcinoma (NSCLC) and to explore the prospect of silencing c-Myc gene in gene therapy of non-small cell lung cancer. Methods: The mRNA expression of c-Myc in 84 non-small cell lung cancer tissues and corresponding paracancerous tissues was detected by real-time fluorescence quantitative PCR. The c-Myc gene siRNA was transiently transfected into H1299 non-small cell lung cancer cell line by Lipofact AMINE2000. The inhibitory effect of c-Myc gene silencing on tumor cells was verified by cisplatin (Cisplatin, cis) toxicity test. The expression of c-Myc gene RNA in H1299 cells was detected by RT-PCR, and the effect of inhibiting cells by CCK-8 assay. Results: The expression of c-Myc m RNA in non-small cell lung cancer tissues was significantly higher than that in corresponding paracancerous tissues (P <0.05). The expression of c-Myc m RNA in H1299 cells transiently transfected with c-Myc si RNA decreased significantly (P <0.05). The c-Myc gene silencing combined with cisplatin can also significantly improve the inhibitory effect of cisplatin on the proliferation of H1299 cells (P <0.05). Conclusion: The expression of c-Myc gene in non-small cell lung cancer tissues was significantly higher than that in adjacent non-small cell lung cancer tissues. The silencing of c-Myc gene significantly enhanced the proliferation of non-small cell lung cancer H1299 cells. The c-Myc gene May become a new target of NSCLC gene therapy.